Intracellular Bacteria and Protozoa - Intracellular Delivery: Fundamentals and Applications - page 805

Morilla MJ, Montanari JA, Prieto MJ, Lopez MO, Petray PB, Romero EL (2004) Intravenous
liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough.
Int J Pharm 278: 311-318
Mosqueira VCF, Loiseau PM, Bories C, Legrand P, Devissaguet JP, Barratt G (2004) Efficacy and
pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium
berghei -infected mice. Antimicrob Agents Chemother 48: 1222-1228.
Mota MM, Rodriguez A (2002) Invasion of mammalian host cells by Plasmodium sporozoites.
Bioessays 24: 149-156
Mugabe C, Azghani AO, Omri A (2006) Preparation and characterization of dehydration-
rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. Int J Pharm 307:
244-250
Mullaicharam AR, Murthy RSR (2004) Lung accumulation of niosome-entrapped rifampicin fol-
lowing intravenous and intratracheal administration in the rat. J Drug Deliv Sci Technol 14:
99-104
Munusamy P, Seleem MN, Alqublan H, Tyler R Jr, Sriranganathan N, Pickrell G (2009) Targeted
drug delivery using silica xerogel systems to treat diseases due to intracellular pathogens.
Mater Sci Eng C 29: 2313-2318
Murray HW, Berman JD, Davies RR, Saravia NG (2005) Advances in Leishmaniasis. Lancet 366:
1561-1577
Murta S, Gazzinelli R, Brener Z, Romanha A (1998) Molecular characterization of susceptible
and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol
Biochem Parasitol 93: 203-214
Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A (2007) Inhalable microparticles con-
taining large payload of anti-tuberculosis drugs. Eur J Pharm Sci 32: 140-150
Myers JP (2005) New recommendations for the treatment of tuberculosis. Curr Opin Infect Dis
18: 133-140
Nagai J, Takano M 2004 Molecular aspects of renal handling of aminoglycosides and strategies
for preventing the nephrotoxicity. Drug Metab Pharmacokinet 19(3): 159-70
Nan A, Croft SL, Yardley V, Ghandehari H (2004) Targetable water-soluble polymer-drug conju-
gates for the treatment of visceral leishmaniasis. J Control Release 94: 115-27
Nelson KG, Bishop JV, Ryan RO, Titus R (2006) Nanodisk-associated amphotericin B clears
leishmanis major cutaneous infection in susceptible Balb/c mice. Antimicrob Agents
Chemother 50: 1238-1244
New RRC, Chance ML, Thomas SC, Peters W (1978) Antileishmanial activity of antimonials
entrapped in liposomes. Nature 272: 55-56
New RRC, Chance ML (1980) Treatment of experimental cutaneous leishmaniasis by liposome-
entrapped Pentostam. Acta Trop 37: 253-256
New RRC, Chance ML, Heath S (1981) The treatment of experimental cutaneous leishmaniasis
with liposome-entrapped Pentostam. Parasitology 83: 519-527
Nicoletti S, Seifert K, Gilbert IH (2009) N-(2-hydroxypropyl)methacrylamide-amphotericin B
(HPMA-AmB) copolymer conjugates as antileishmanial agents. Int J Antimicrob Agents 33:
441-448
Nicoletti S, Seifert K, Gilbert IH (2010) Water-soluble polymer-drug conjugates for combination
chemotherapy against visceral leishmaniasis. Bioorg Med Chem 18: 2559-2565
Nix DE, Goodwin D, Peloquin CA, Rotella DL, Schentag JJ (1991) Antibiotic tissue penetration
and its relevance: models of tissue penetration and their meaning. Antimicrob Agents
Chemother 35: 1947-1950
Nogueira N, Cohn Z (1976) Trypanosoma cruzi : mechanism of entry and intracellular fate in
mammalian cells. J Exp Med 143: 1402-1420
Ohashi K, Kabasawa T, Ozeki T, Okada H (2009) One-step preparation of rifampicin/ poly(lactic-co-
glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray
drier for inhalation therapy of tuberculosis. J Control Release 135: 19-24
Onoue S, Misaka S, Kawabata Y, Yamada S (2009) New treatments for chronic obstructive
pulmonary disease and viable formulation/device options for inhalation therapy. Expert Opin
Drug Deliv 6: 793-811